Loading…
Centrient Pharmaceuticals India Private Limited, an active pharmaceutical ingredient (API) manufacturer in Punjab, was cited for significant current good manufacturing practice (CGMP) violations that rendered their APIs adulterated. FDA investigators documented failures in quality unit oversight, including inadequate document control with uncontrolled storage of logbooks and forms, improper handling of documents in an unlabeled emergency shredder, and insufficient controls over computerized systems with multiple users sharing login credentials. These deficiencies represented a systemic breakdown in the company's ability to ensure API compliance with manufacturing standards during the June-July 2022 inspection.